Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Judith Atz"'
Autor:
Christian Grohé, Thomas Wehler, Tobias Dechow, Sven Henschke, Wolfgang Schuette, Ina Dittrich, Stefan Hammerschmidt, Harald Müller-Huesmann, Christian Schumann, Stefan Krüger, Judith Atz, Rolf Kaiser
Publikováno v:
Translational Lung Cancer Research. 11:2010-2021
Immune checkpoint inhibitors (ICIs) with or without chemotherapy represent first-line standard of care for patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. The most appropriate second-line therapy after f
Autor:
Filippo Rizzo, Diana Schaufler, Jens Panse, Matthias Scheffler, Kato Kambartel, Martin Metzenmacher, Judith Atz, Amin T. Turki, Christopher M. Hoffmann, Hannes Buchner, Mathias Hoiczyk, Daniel C. Christoph, Ivo Azeh
Publikováno v:
Future oncology 17(30), 3965-3976 (2021). doi:10.2217/fon-2021-0424
Future oncology 17(30), 3965-3976 (2021). doi:10.2217/fon-2021-0424
Published by Future Medicine Ltd, London
Published by Future Medicine Ltd, London
Autor:
Judith Atz, Christian Franke, Nadezda Basara, Siegfried Haas, Rolf Kaiser, Wolfgang Gleiber, Christoph Losem, Christian Grohé, M. Schulze, Harald Mueller-Huesmann
Publikováno v:
Future Oncology. 15:2699-2706
Aim: To assess outcomes in patients with advanced adenocarcinoma non-small-cell lung cancer who received nintedanib plus docetaxel after progression on prior chemotherapy followed by immune checkpoint inhibitor (ICI) therapy. Patients & methods: VARG
Autor:
Christian Grohé, Thomas Wehler, Sven Henschke, Ina Dittrich, Stefan Hammerschmidt, Christoph Aulmann, Tobias Dechow, Conrad Schiefer, Ingo Zander, Wolfgang Schuette, Judith Atz, Rolf Kaiser
Publikováno v:
Journal of Clinical Oncology. 40:9092-9092
9092 Background: ICIs with or without chemotherapy represent 1L standard of care for patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. Given the paucity of prospective randomized trials assessing second-li
Autor:
S. Hammerschmidt, W. Schütte, S. Henschke, Christian Grohé, I. Dittrich, Judith Atz, C. Schumann, Tobias Dechow, T. Wehler, Stefan Krüger, H. Müller-Huesmann, Roselinde H. Kaiser
Publikováno v:
Annals of Oncology. 32:S1018-S1019
Autor:
T. Wehler, Ina Dittrich, Tobias Dechow, Judith Atz, Sven Henschke, Christian Grohé, Christian Schumann, Stefan Hammerschmidt, Wolfgang Schuette, Rolf Kaiser, H. Müller-Huesmann, Stefan Krüger
Publikováno v:
Journal of Clinical Oncology. 39:9033-9033
9033 Background: The treatment landscape in advanced non-small cell lung cancer (NSCLC) has undergone significant changes, with immune checkpoint inhibitor (ICI) +/- chemotherapy now the preferred first-line (1L) regimen for metastatic, non-mutated N
Autor:
S. Hammerschmidt, Stefan Krüger, T. Wehler, Christian Grohé, S. Haas, Wolfgang Gleiber, H. Mueller-Huesmann, M. Schulze, Roselinde H. Kaiser, Judith Atz
Publikováno v:
Annals of Oncology. 31:S875-S876
Autor:
Judith Atz, M. Schulze, Rolf Kaiser, Siegfried Haas, Wolfgang Blau, Harald Mueller-Huesmann, Wolfgang Gleiber, Stefan Krüger, Christian Grohé
Publikováno v:
Journal of Clinical Oncology. 38:9604-9604
9604 Background: Nintedanib (Vargatef) is an oral triple angiokinase inhibitor targeting VEGF-, PDGF- and FGF receptor pathways. It is approved in the EU and other countries in combination with docetaxel for treatment of locally advanced, metastatic
Autor:
Stefan Krüger, Judith Atz, Christian Grohé, Roselinde H. Kaiser, Wolfgang Gleiber, S. Haas, M. Schulze
Publikováno v:
Annals of Oncology. 30:v618
Background Nintedanib (Vargatef®) is an oral triple angiokinase inhibitor of VEGF-, PDGF- and FGF-receptors approved in the EU and other countries in combination with docetaxel for treatment of locally advanced, metastatic or locally recurrent NSCLC
Autor:
M. Schulze, Harald Mueller-Huesmann, Wolfgang Blau, Christian Grohé, Judith Atz, Rolf Kaiser, Wolfgang Gleiber, Siegfried Haas
Publikováno v:
Journal of Clinical Oncology. 37:9074-9074
9074 Background: The treatment landscape of non-targetable advanced NSCLC pts has changed considerably following the introduction of ICIs. Data are scarce regarding optimal treatment choice and treatment sequence for pts who progressed on ICI. Method